Skip to content

The safety and efficacy of human umbilical cord mesenchymal stem cell-derived extracellular vesicles in the treatment of Crohn's disease with refractory anal fistula: A prospective, single-center, single-arm study.

The safety and efficacy of human umbilical cord mesenchymal stem cell-derived extracellular vesicles in the treatment of Crohn's disease with refractory anal fistula: A prospective, single-center, single-arm study.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099956
Enrollment
Unknown
Registered
2025-04-01
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Interventions

Experimental group:UCMSC-Exo Injection
UCMSC-Exo Enteric-Coated Capsules.

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Medical History Requirements: Patients aged 18-60 years, diagnosed with Crohn's Disease (CD) for more than six months, and presenting with complex anal fistulas that are uncontrolled or intolerant to at least one advanced therapy (biologics or small-molecule drugs). 2.Active Fistula Score: Patients must have an active perianal disease activity index (Perianal Disease Activity Index, PDAI > 4) at the time of enrollment and meet the diagnostic criteria for complex anal fistulas. 3.Follow-up Commitment: Willingness to undergo regular outpatient or telephone follow-ups after discharge. 4.Pregnancy Test: Female participants must have a negative (blood or urine) pregnancy test.

Exclusion criteria

Exclusion criteria: 1. Rectal or anal stricture; 2. Active severe proctitis: defined as the presence of extensive superficial or deep ulcers, which may affect the healing of the postoperative fistula; 3. Perianal abscess >=2 cm in diameter; 4. Have not received treatment for anal fistula in Crohn's disease in the past; 5. Treatment with corticosteroids within the past 4 weeks; 6. Allergy to MSC-Exos or related ingredients; 7. Combined with serious infection or other uncontrollable systemic diseases; 8. Pregnant or lactating women; 9. Unwillingness to accept measures to avoid pregnancy; 10. Patients who have participated in other clinical trials within 4 weeks; 11. Other reasons why the investigator evaluation cannot be selected.

Design outcomes

Primary

MeasureTime frame
PDAI score and clinical fistula healing rate;

Secondary

MeasureTime frame
Abdominal pain score (APS) ;MRI fistula activity score;Frequency of loose or watery stools (SF);S-IBDQ (Simplified Inflammatory Bowel Disease Questionnaire) scores.;

Countries

China

Contacts

Public ContactWeifeng Huang

The First Affiliated Hospital of Xiamen University

hwf0625@163.com+86 18150906129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026